Together, PDE6D might affect diverse cytoplasmatic and nuclear pathways in HCC and potentially also in other cancer types, which should be explored together with its strong potential as a novel therapeutic and diagnostic target in HCC progression and chemoresistance. This evidence concerns the gene PDE6D and cancer.